Rebekka Jerjen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebekka Jerjen has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Rodney Sinclair
Sinclair Dermatology East Melbourne Victoria Australia
7 shared publications Dmitri Wall
Sinclair Dermatology Melbourne VIC Australia
3 shared publicationsNekma Meah
Sinclair Dermatology Melbourne VIC Australia
3 shared publications- Nekma Meah
Centre for Dermatology Research, Faculty of Biology, Medicine and Health, University of Manchester & NIHR Biomedical Research Centre, Manchester, UK
3 shared publications Ameshin Moodley
Sinclair Dermatology, East Melbourne, Victoria, Australia
2 shared publications- Bevin Bhoyrul
Sinclair Dermatology, East Melbourne, Victoria, Australia
2 shared publications
Latest Publications
- 18 November 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (1)
A Meta‐Analysis of the Prevalence of Mismatch Repair Germline Mutations in Patients With Sebaceous Neoplasms: Are We Missing an Opportunity for Lynch Syndrome Detection?
Sebaceous neoplasms are rare skin tumours linked with Lynch syndrome (LS), particularly the Muir‐Torre syndrome (MTS) variant. They present an opportunity for early LS detection due to their association with mismatch repair (MMR) gene pathogenic variants. This study aims to provide an accurate estimate of LS prevalence among patients with sebaceous adenomas and carcinomas. We performed a systematic review and meta‐analysis of studies published between 2005 and 2024. Eligible studies utilised germline testing for MMR mutations. The studies were stratified by diagnostic approach and analysed using proportional meta‐analysis to determine LS prevalence. Subgroup analyses were conducted by population characteristics and diagnostic criteria. Lynch Syndrome prevalence among patients with sebaceous neoplasms varied across the 9 studies that met eligibility criteria, ranging from 0.8% to 29.0%. LS among patients with sebaceous carcinomas was 6.6% (95% CI: 3.6%–9.5%). Population‐based studies had a higher LS identification rate (10.6%), while multi‐centre and single‐centre studies reported lower rates. Studies using a history suggestive of MTS or MMR‐deficient tumours as criteria showed the highest LS prevalence. Male patients had higher sebaceous neoplasms prevalence, with LS‐positive cases presenting at a younger age than typical sporadic cases. Our findings highlight the potential for LS detection in patients with sebaceous neoplasms, particularly those with MMR deficiency or a suggestive MTS history. Increased testing in this group could facilitate early LS detection, improving outcomes through screening and preventive strategies. Universal MMR testing for sebaceous tumours warrants consideration as a strategy to capture at‐risk LS patients.
- 18 November 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (1)
A Meta‐Analysis of the Prevalence of Mismatch Repair Germline Mutations in Patients With Sebaceous Neoplasms: Are We Missing an Opportunity for Lynch Syndrome Detection?
Sebaceous neoplasms are rare skin tumours linked with Lynch syndrome (LS), particularly the Muir‐Torre syndrome (MTS) variant. They present an opportunity for early LS detection due to their association with mismatch repair (MMR) gene pathogenic variants. This study aims to provide an accurate estimate of LS prevalence among patients with sebaceous adenomas and carcinomas. We performed a systematic review and meta‐analysis of studies published between 2005 and 2024. Eligible studies utilised germline testing for MMR mutations. The studies were stratified by diagnostic approach and analysed using proportional meta‐analysis to determine LS prevalence. Subgroup analyses were conducted by population characteristics and diagnostic criteria. Lynch Syndrome prevalence among patients with sebaceous neoplasms varied across the 9 studies that met eligibility criteria, ranging from 0.8% to 29.0%. LS among patients with sebaceous carcinomas was 6.6% (95% CI: 3.6%–9.5%). Population‐based studies had a higher LS identification rate (10.6%), while multi‐centre and single‐centre studies reported lower rates. Studies using a history suggestive of MTS or MMR‐deficient tumours as criteria showed the highest LS prevalence. Male patients had higher sebaceous neoplasms prevalence, with LS‐positive cases presenting at a younger age than typical sporadic cases. Our findings highlight the potential for LS detection in patients with sebaceous neoplasms, particularly those with MMR deficiency or a suggestive MTS history. Increased testing in this group could facilitate early LS detection, improving outcomes through screening and preventive strategies. Universal MMR testing for sebaceous tumours warrants consideration as a strategy to capture at‐risk LS patients.
- 14 October 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (5) , A12-A62
Table of Contents
- 14 October 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (5) , A12-A62
Table of Contents
- 20 August 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (12) , 2440-2447
Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study
Background: Fibrosing alopecia in a pattern distribution (FAPD) is a primary cicatricial alopecia considered a subtype of lichen planopilaris (LPP).Objective: The clinical and histopathological features, and treatment response of 24 female patients with FAPD were evaluated.Methods: Demographic, clinical, histopathological and treatment data of patients with FAPD were retrospectively collected.Results: Twenty‐four women were included (mean age 60.7 years). The mean Lichen Planopilaris Activity Index score was 1.50, and the median Sinclair grade was 3. Twelve patients had diffuse alopecia in the centroparietal region, four had frontal accentuation and eight had vertex accentuation of hair loss. Eight had associated loss of facial hair. Predominant trichoscopic features included hair shaft diameter variability (100%), perifollicular erythema and/or scaling (95%) and loss of follicular ostia (95%). Histopathological examination revealed features of scarring alopecia with interface changes in follicular epithelia mainly targeting terminal and intermediate hairs, and less frequently, vellus hairs. Treatment with hair growth‐promoting, anti‐inflammatory and anti‐androgen agents arrested disease progression in 14 patients and resulted in hair regrowth in two patients. Six patients had progression of their hair loss in spite of treatment.Limitations: Referral bias to a specialist hair clinic, retrospective design and small sample size.Conclusions: We present clinicopathological features of FAPD which can aid in the diagnosis of this insidious scarring alopecia. Our findings suggest a more favourable outcome if treatment is initiated in early stages of the disease.
- 20 August 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (12) , 2440-2447
Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study
Background: Fibrosing alopecia in a pattern distribution (FAPD) is a primary cicatricial alopecia considered a subtype of lichen planopilaris (LPP).Objective: The clinical and histopathological features, and treatment response of 24 female patients with FAPD were evaluated.Methods: Demographic, clinical, histopathological and treatment data of patients with FAPD were retrospectively collected.Results: Twenty‐four women were included (mean age 60.7 years). The mean Lichen Planopilaris Activity Index score was 1.50, and the median Sinclair grade was 3. Twelve patients had diffuse alopecia in the centroparietal region, four had frontal accentuation and eight had vertex accentuation of hair loss. Eight had associated loss of facial hair. Predominant trichoscopic features included hair shaft diameter variability (100%), perifollicular erythema and/or scaling (95%) and loss of follicular ostia (95%). Histopathological examination revealed features of scarring alopecia with interface changes in follicular epithelia mainly targeting terminal and intermediate hairs, and less frequently, vellus hairs. Treatment with hair growth‐promoting, anti‐inflammatory and anti‐androgen agents arrested disease progression in 14 patients and resulted in hair regrowth in two patients. Six patients had progression of their hair loss in spite of treatment.Limitations: Referral bias to a specialist hair clinic, retrospective design and small sample size.Conclusions: We present clinicopathological features of FAPD which can aid in the diagnosis of this insidious scarring alopecia. Our findings suggest a more favourable outcome if treatment is initiated in early stages of the disease.
- 6 January 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (2) , E345-E347
Effective treatment of folliculitis decalvans with cyclosporin: A case series
- 6 January 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (2) , E345-E347
Effective treatment of folliculitis decalvans with cyclosporin: A case series
- 24 December 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (5) , 977-978
Low‐dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome
Loose anagen hair syndrome (LAHS) is a sporadic or autosomal dominant hair disorder which typically affects girls aged 2‐6 years.1 It is characterised by increased hair shedding, non‐scarring alopecia, inability to grow long hair, dull and lustreless hair. Premature and defective keratinisation of the inner root sheath (IRS), and impaired anchorage of anagen hairs underlie the pathogenesis.1 A favourable response has been demonstrated in three patients with LAHS treated with topical minoxidil.1–3 Low‐dose oral minoxidil (LDOM) has been shown to be effective in adult androgenetic alopecia, alopecia areata and telogen effluvium.4 Herein we describe the efficacy and safety of LDOM in LAHS.
- 24 December 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (5) , 977-978
Low‐dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome
Loose anagen hair syndrome (LAHS) is a sporadic or autosomal dominant hair disorder which typically affects girls aged 2‐6 years.1 It is characterised by increased hair shedding, non‐scarring alopecia, inability to grow long hair, dull and lustreless hair. Premature and defective keratinisation of the inner root sheath (IRS), and impaired anchorage of anagen hairs underlie the pathogenesis.1 A favourable response has been demonstrated in three patients with LAHS treated with topical minoxidil.1–3 Low‐dose oral minoxidil (LDOM) has been shown to be effective in adult androgenetic alopecia, alopecia areata and telogen effluvium.4 Herein we describe the efficacy and safety of LDOM in LAHS.
- 1 November 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (4) , 376-377
The Bairnsdale ulcer (Mycobacterium ulcerans) in an urban Victorian practice: A case series
- 1 November 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (4) , 376-377
The Bairnsdale ulcer (Mycobacterium ulcerans) in an urban Victorian practice: A case series
- 25 October 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (1) , 103-108
Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
Background: Alopecia areata (AA) is an autoimmune hair loss condition that affects people of all ages. Early age of onset and prolonged disease duration indicate poor prognosis. Janus kinase inhibitors are being investigated in phase 3 clinical trials in adolescents and adults with AAObjective: To evaluate the use of oral tofacitinib in pre‐adolescent patients with AA.Methods: A retrospective review of case records of all pre‐adolescent patients with AA treated with oral tofacitinib in a single center between 2018 and 2019.Results: Fourteen patients were identified, aged 7 to 11 years. Nine patients experienced clinically significant improvement in their SALT (Severity of Alopecia Tool) score. Three patients achieved complete remission (SALT score of 0), seven (63.6%) achieved over 50% improvement in SALT score from baseline. One patient had no change from baseline, another experienced additional hair loss. After an average of 9 months of treatment, the median SALT score improvement was 67.7%. The improvement was similar in patients with baseline SALT scores greater than 50 and those with baseline SALT scores below 10. Adverse events were mild.Limitations: The retrospective nature of the data, small sample size, lack of a control group, referral bias to a specialist hair center, and concomitant use of other medications including oral minoxidil in all patients.Conclusion: There is a role for tofacitinib as a systemic therapy in AA and this should be further evaluated in prospective clinical trials in pre‐adolescents.
- 25 October 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (1) , 103-108
Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
Background: Alopecia areata (AA) is an autoimmune hair loss condition that affects people of all ages. Early age of onset and prolonged disease duration indicate poor prognosis. Janus kinase inhibitors are being investigated in phase 3 clinical trials in adolescents and adults with AAObjective: To evaluate the use of oral tofacitinib in pre‐adolescent patients with AA.Methods: A retrospective review of case records of all pre‐adolescent patients with AA treated with oral tofacitinib in a single center between 2018 and 2019.Results: Fourteen patients were identified, aged 7 to 11 years. Nine patients experienced clinically significant improvement in their SALT (Severity of Alopecia Tool) score. Three patients achieved complete remission (SALT score of 0), seven (63.6%) achieved over 50% improvement in SALT score from baseline. One patient had no change from baseline, another experienced additional hair loss. After an average of 9 months of treatment, the median SALT score improvement was 67.7%. The improvement was similar in patients with baseline SALT scores greater than 50 and those with baseline SALT scores below 10. Adverse events were mild.Limitations: The retrospective nature of the data, small sample size, lack of a control group, referral bias to a specialist hair center, and concomitant use of other medications including oral minoxidil in all patients.Conclusion: There is a role for tofacitinib as a systemic therapy in AA and this should be further evaluated in prospective clinical trials in pre‐adolescents.
- 22 September 2020
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (7) , 1024-1025
Ulerythema Ophryogenes Mimicking Frontal Fibrosing Alopecia
- 22 September 2020
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (7) , 1024-1025
Ulerythema Ophryogenes Mimicking Frontal Fibrosing Alopecia
- 11 September 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (1) , 93-94
Effective treatment of disseminated superficial actinic porokeratosis using a novel topical cholesterol/simvastatin combination cream
- 11 September 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (1) , 93-94
Effective treatment of disseminated superficial actinic porokeratosis using a novel topical cholesterol/simvastatin combination cream
- 6 August 2020
- Published by Wiley in International Journal of Dermatology
- Vol. 59 (11) , E388-E389
Duration of remission after recovery from the first episode of alopecia areata
- 6 August 2020
- Published by Wiley in International Journal of Dermatology
- Vol. 59 (11) , E388-E389
Duration of remission after recovery from the first episode of alopecia areata